AT-527
COVID-19
Phase 2Partnered (Roche)
Key Facts
About Atea Pharmaceuticals
Atea Pharmaceuticals is a Boston-based biotech focused on discovering and developing oral antiviral therapies for RNA viruses, leveraging a proprietary platform of purine nucleos(t)ide prodrugs. Its lead asset, a combination of bemnifosbuvir (polymerase inhibitor) and ruzasvir (NS5A inhibitor), is in Phase 3 development for hepatitis C with topline data expected in 2026. Founded by antiviral veteran Jean-Pierre Sommadossi, the company's strategy targets significant unmet needs in HCV and other RNA viral diseases with convenient oral regimens designed for high efficacy and a high barrier to resistance.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |